Patents by Inventor J. H. David Wu

J. H. David Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Promoters and proteins from and uses thereof
    Patent number: 8309324
    Abstract: The present invention relates to an inducible and a high expression nucleic acid promoter isolated from Clostridium thermocellum. These promoters are useful for directing expression of a protein or polypeptide encoded by a nucleic acid molecule operably associated with the nucleic acid promoters. The present invention also relates to nucleic acid constructs including the C. thermocellum promoters, and expression vectors and hosts containing such nucleic acid constructs. The present invention also relates to protein isolated from Clostridium thermocellum, including a repressor protein. The present invention also provides methods of using the isolated promoters and proteins from Clostridium thermocellum, including methods for directing inducible in vitro and in vivo expression of a protein or polypeptide in a host, and methods of producing ethanol from a cellulosic biomass.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: November 13, 2012
    Assignee: University of Rochester
    Inventors: J. H. David Wu, Michael Newcomb
  • Human heme-regulated initiation factor 2-alpha kinase
    Patent number: 7235636
    Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: June 26, 2007
    Assignee: University of Rochester
    Inventors: J. H. David Wu, Takeshi Omasa, Athanassios Mantalaris, Yi-Guang Chen, Ying-Chuech Tsai
  • Ex vivo generation of functional leukemia cells in a three-dimensional bioreactor
    Patent number: 7087431
    Abstract: The present invention provides cultured leukemia cells. The method comprises isolating mononuclear cells, which contain leukemia cells, culturing the leukemia cells in a chamber having a scaffolding covered or surrounded with culture medium, where the scaffolding allows for leukemia cells to have cell to cell contacts in three dimensions. The subject leukemia cells are useful for screening compounds which inhibit or stimulate leukemia cell function or formation.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: August 8, 2006
    Assignee: University of Rochester
    Inventors: J. H. David Wu, Athanassios Mantalaris, Nicki Panoskaltsis
  • Human heme-regulated initiation factor 2-alpha kinase
    Publication number: 20030188328
    Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.
    Type: Application
    Filed: May 5, 2003
    Publication date: October 2, 2003
    Inventors: J. H. David Wu, Takeshi Omasa, Athanassios Mantalaris, Yi-Guang Chen, Ying-Chuech Tsai
  • Human heme-regulated initiation factor 2-&agr; kinase
    Patent number: 6562571
    Abstract: The present invention provides an isolated nucleic acid sequence encoding a human heme-regulated initiation factor 2 alpha kinase. In addition, the invention provides a method for inhibiting protein synthesis, inducing cellular differentiation, or inhibiting infection in human cells by administering an effective amount of a heme-regulated initiation factor 2 alpha kinase to the cells. Methods are also provided for for modulating heme-regulated initiation factor 2 alpha kinase activity and determining the level of heme-regulated initiation factor 2 alpha kinase expression.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: May 13, 2003
    Assignee: University of Rochester
    Inventors: J. H. David Wu, Takeshi Omasa, Athanassios Mantalaris, Yi-Guang Chen, Ying-Chuech Tsai